Story perspectives

Democrats Slam TrumpRx for Drug Price Transparency Issues

10/24/2025

48 11

Summary

Story summary

Democratic leaders criticized the TrumpRx platform for potentially benefiting pharmaceutical firms tied to U.S. President Donald Trump and not lowering drug prices.
They criticized the lack of transparency in pricing agreements with Pfizer and AstraZeneca.
They raised concerns about BlinkRx conflicts of interest, linked to Donald Trump Jr., and sought clarification on operations.
Roche reported disappointing sales but raised its earnings forecast, citing tariff mitigation and obesity-market expansion.

1 of 1

Story summary

Democratic leaders criticized the TrumpRx platform for potentially benefiting pharmaceutical firms tied to U.S. President Donald Trump and not lowering drug prices.
They criticized the lack of transparency in pricing agreements with Pfizer and AstraZeneca.
They raised concerns about BlinkRx conflicts of interest, linked to Donald Trump Jr., and sought clarification on operations.
Roche reported disappointing sales but raised its earnings forecast, citing tariff mitigation and obesity-market expansion.